Altogether, this evidence supports the view that complex and distinct mechanisms, mainly involving CerS1-6 and/or DES1 enzymes, can control de novo generated Cer levels in BC cells (Table 1) and support further efforts to confirm CerS and/or DES1 as potential therapeutic targeting. The gene discussed is DEGS1; the disease is breast cancer.